Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097440 | 0.94 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL9906197 | 0.94 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL24828881 | 0.90 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL19479169 | 0.89 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL19157450 | 0.89 | FOLH1 (0.37) | FOLH1CHIT1DPP4 | |
| SCHEMBL13558125 | 0.87 | GRIN1 (0.35) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL999924 | 0.86 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL16925973 | 0.86 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL5864681 | 0.86 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL1079076 | 0.86 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | GRIN1 1051/4885GRIN2A 1680/4885GRIN2B 1860/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | GRIN1 931/4885GRIN2A 1593/4885GRIN2B 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.